CORAL SPRINGS, Florida, February 14, 2013 /PRNewswire/ --
FinancialNewsMedia.com "Active Health Stocks to Watch" for today: Crown Marketing Pharmaceuticals, Amarin Corporation (NASDAQ: AMRN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Eli Lilly and Company (NYSE: LLY), Medtronic, Inc. (NYSE: MDT), RPX Corporation (NASDAQ: RPXC).
Crown Marketing Pharmaceuticals closed up over 16% in trading yesterday closing at $0.128 per share. Crown Marketing Pharmaceuticals announced today that Patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in South Africa. This is Crown Marketing Pharmaceuticals's second major announcement regarding the approval of new Patents following last week's news it had also secured Patents in Norway. Crown is continuing to secure its worldwide patent rights as it pursues novel applications of its drug delivery technology. Crown Marketing Pharmaceuticals also announced last week on February 7th the company has begun to review positive in vivo test results by examining blood plasma levels in test subjects using Crown's Controlled Drug Delivery Technology (CDDT). A clinical trial was conducted using 300 mg of Dexibuprofren Lysine and found that the blood plasma levels tracked the in vitro test results conducted earlier. The clinical trial appears to validate our belief and claims that because of the controllable diffusion dynamics and our mathematical modeling, we can predict with a high degree of certainty the release kinetics. For more details regarding Crown's CDDT applications, go to http://crowncddt.com/technology/
Stay informed on Crown Marketing developments by getting FREE news alerts & updates delivered directly to your mobile phone by texting STOCK to 545454 from your cellular device or visit http://cwnm.mobi for more details.
Amarin Corporation plc (NASDAQ: AMRN) closed up in trading yesterday closing at $8.58 per share on 2.84Million shares. AMRN is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, that announced this week that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/614,129. This application includes claims intended to protect the Vascepa (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) closed up slightly in trading yesterday closing at $7.11 per share on 5.47Million shares. KERX is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.
Eli Lilly and Company (NYSE: LLY) closed up slightly in trading yesterday closing at $53.44 per share on 4.38Million shares. An announcement was issued after the close yesterday that LLY has entered into a master collaboration agreement with QIAGEN (NASDAQ: QGEN) for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on QIAGEN and Lilly's past work together. Companion diagnostics unlock a patient's molecular information in order to guide treatment decisions for specific cancers or other diseases. Financial terms of the agreement are not being disclosed.
Medtronic, Inc. (NYSE: MDT) closed down slightly in trading yesterday closing at $46.99 per share on 3.04Million shares, but was up in After-Market trading. MDT announced after the markets closed on Wednesday that it has received Food and Drug Administration (FDA) clearance for its AIRvance(TM) Bone Screw System that allows surgeons to perform a hyoid suspension procedure independently or in combination with other procedures for the treatment of obstructive sleep apnea (OSA). Under the previous FDA clearance the hyoid suspension procedure was indicated as an adjunct to the tongue suspension procedure. This latest FDA clearance makes the AIRvance System the only combined system available for performing a hyoid suspension procedure as well a tongue suspension procedure.
RPX Corporation (NASDAQ: RPXC) closed up over 22% in trading yesterday closing at $13.05 pre share on 1.1Million shares. RPXC is a leading provider of patent risk management solutions, announced yesterday its financial results for the fourth quarter and year ended December 31, 2012. RPXC Revenue for the fourth quarter of fiscal 2012 totaled $51.6 million, up 22% from the prior year period and Revenue for fiscal 2012 totaled $197.7 million, up 28% from fiscal 2011. "RPX reported a solid 2012, capped by a strong fourth quarter with progress in client growth, patent acquisition activity, and the roll out of our insurance service," said Chief Executive Officer John Amster.
Other Healthcare companies to monitor for new developments are Bond Laboratories, Inc (BNLB), an international provider of innovative and proprietary nutritional supplements for health conscious consumers; YaFarm Technologies, Inc. (YFRM) subsidiary, The Integrative Stem Cell Institute (ISCI), is a premier provider of point-of-care, stem cell-based therapies; and Bio-Matrix Scientific Group, Inc. (BMSN), a biotechnology company developing regenerative medicine therapies.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.